Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells 70,000 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director David S. Kabakoff sold 70,000 shares of the firm’s stock in a transaction on Monday, April 5th. The shares were sold at an average price of $72.20, for a total transaction of $5,054,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ:CSTL opened at $70.54 on Thursday. Castle Biosciences, Inc. has a 12 month low of $26.13 and a 12 month high of $107.69. The business has a 50-day moving average of $71.50 and a two-hundred day moving average of $64.11. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.65 and a quick ratio of 6.59. The firm has a market capitalization of $1.76 billion, a PE ratio of -414.92 and a beta of 0.46.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Sunday, March 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.12). Castle Biosciences had a negative return on equity of 2.69% and a negative net margin of 5.30%. The company had revenue of $17.30 million during the quarter, compared to the consensus estimate of $15.74 million. During the same period last year, the business posted $0.11 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, research analysts anticipate that Castle Biosciences, Inc. will post -0.4 earnings per share for the current year.

Several equities research analysts recently issued reports on CSTL shares. Zacks Investment Research cut Castle Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, March 11th. Canaccord Genuity increased their target price on Castle Biosciences from $80.00 to $84.00 and gave the stock a “buy” rating in a research note on Tuesday, January 26th. BTIG Research lifted their price objective on Castle Biosciences from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, December 17th. Robert W. Baird cut their price target on Castle Biosciences from $87.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 9th. Finally, SVB Leerink boosted their target price on Castle Biosciences from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Friday, January 15th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Castle Biosciences currently has a consensus rating of “Buy” and an average price target of $79.50.

A number of hedge funds and other institutional investors have recently modified their holdings of CSTL. Cambridge Investment Research Advisors Inc. increased its position in shares of Castle Biosciences by 2.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 6,945 shares of the company’s stock valued at $466,000 after purchasing an additional 178 shares during the period. Penserra Capital Management LLC grew its holdings in Castle Biosciences by 173.8% during the fourth quarter. Penserra Capital Management LLC now owns 460 shares of the company’s stock worth $30,000 after acquiring an additional 292 shares during the period. Panagora Asset Management Inc. boosted its position in shares of Castle Biosciences by 2.3% during the 4th quarter. Panagora Asset Management Inc. now owns 16,119 shares of the company’s stock valued at $1,082,000 after purchasing an additional 368 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Castle Biosciences by 6.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,703 shares of the company’s stock worth $345,000 after purchasing an additional 396 shares during the last quarter. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Castle Biosciences in the 4th quarter worth approximately $27,000. 66.42% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.